(Boursier.com) — Guerbet stands out at the start of the session thanks to a gain of 6.8% to 17.4 euros. It must be said that the specialist in contrast products announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion for the granting of marketing authorization. market of Elucirem (Gadopiclenol) in the European Union for its use in adults and children aged 2 years and older for MRI with contrast enhancement. The European Commission is expected to make its decision by the end of 2023. Guerbet believes that if approved by the EC, Elucirem will represent an important innovation in MRI contrast agents, thus addressing the concerns of patients and doctors. radiologists in Europe. An MRI exam with Elucirem requires half the dose of gadolinium compared to existing non-specific contrast products.
Portzamparc (‘purchase’) speaks of excellent news for the group. This first step was expected and should be followed by the end of 2023 by the issuance of the Marketing Authorization by the European Commission, thus allowing marketing in the first half of 2024. The broker recalls that Elucirem was approved by the FDA in September 2022 and should generate turnover of around €15 million in the United States in H2 2023 according to management.
©2023 Boursier.com